The Latest Breaking News from argenx

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Argenx stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study.

The Dow Jones pushed higher, but the Nasdaq slipped despite strong software earnings and a Fed shift toward rate cuts. Tesla Cybertruck deliveries began.

Argenx stock plummeted Tuesday after the company's drug unexpectedly failed to help patients with a rare blood disorder.

Argenx put up another strong quarter for immunology drug Vyvgart on Tuesday, but the biotech stock pulled back from bullish gains.